Diana Carvalho

Diana Carvalho

Auto-generated profile, based on publicly available information

Diana Carvalho

Institute of Cancer Research , London , United Kingdom

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Maria VinciMaria Vinci
Maria Vinci
ABAnna Burford
Anna Burford
VMValeria Molinari
Valeria Molinari
KKKetty Kessler
Ketty Kessler
SPSergey Popov
Sergey Popov
CJChris Jones
Chris Jones

1 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
PKPrasidda Khadka
Prasidda Khadka
ZRZachary J. Reitman
Zachary J. Reitman
SLSophie Lu
Sophie Lu
GBGraham Buchan
Graham Buchan
GGGabrielle Gionet
Gabrielle Gionet
PBPratiti Bandopadhayay
Pratiti Bandopadhayay
The role of PPM1D mutations in de novo gliomagenesis has not been systematically explored. Here we analyze whole genome sequences of 170 pediatric high-grade gliomas and find that truncating mutations in PPM1D that increase the stability of its phosphatase are clonal driver events in 11% of Diffuse Midline Gliomas (DMGs) and are enriched in primary pontine tumors. Through the development of DMG mouse models, we show that PPM1D mutations potentiate gliomagenesis and that PPM1D phosphatase activity is required for in vivo oncogenesis. Finally, we apply integrative phosphoproteomic and functional genomics assays and find that oncogenic effects of PPM1D truncation converge on regulators of cell cycle, DNA damage response, and p53 pathways, revealing therapeutic vulnerabilities including MDM2 inhibition.

28 March 2022 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
MSMafalda Santiago
Mafalda Santiago
FSFrancisco Stocker
Francisco Stocker
PMPaula Ministro
Paula Ministro
RGRaquel Gonçalves
Raquel Gonçalves
DCDiana Carvalho
Diana Carvalho
Fernando MagroFernando Magro
Fernando Magro
INTRODUCTION: Inflammatory bowel disease (IBD) affects people from all age categories worldwide. Although the incidence of the disease is stabilizing or decreasing in most Western world countries, its prevalence is still increasing because of the rise in life expectancy and better disease management. This work intends to identify the trends related to IBD incidence nationwide, analyzing regional, sex, and age distributions. METHODS: Data were provided by the Portuguese Shared Services of the Ministry of Health. This study consisted of a retrospective analysis of all first consultations coded for “Chronic enteritis/ulcerative colitis” (D94) in a primary healthcare setting, between 2017 and 2020, in Portugal. The primary outcome measure was the IBD incidence rate per 100,000 inhabitants. We also calculated the incidence rate per person-year and forecasted incidence until 2024. RESULTS: Between 2017 and 2019, the incidence rate of IBD in Portugal decreased from 54.9 to 48.6 per 100,000 inhabitants. The average incidence was 20 new cases of IBD per 1,000 person-year. It was predicted that, in December 2023, IBD incidence would reach 305.4 new cases (95% Prediction Interval 156.6–454.3), a similar result to the values forecasted for December 2021 (305.4, 95% Prediction Interval 197.3–413.6). DISCUSSION: The incidence of IBD slightly declined from 2017 to 2019, and it is posed to stabilize in the future. The presented data are of the utmost importance for the characterization of IBD in Southern European countries and the establishment of future health policies in the setting of compounding prevalence in the Western world.

14 December 2021 in United European Gastroenterology Journal
Verified
Journal Article
Open access
PDF file
Fernando MagroFernando Magro
Fernando Magro
CACatarina Alves
Catarina Alves
MSMafalda Santiago
Mafalda Santiago
PMPaula Ministro
Paula Ministro
PLPaula Lago
Paula Lago
OGon behalf GEDII (Portuguese IBD Group)
on behalf GEDII (Portuguese IBD Group)
Background: Ulcerative colitis (UC) has been the focus of numerous observational studies over the years and a common strategy employed in their design is the use of composite and aggregate outcomes.Objective: This systematic review and meta‐analysis aims to identify composite and aggregate outcomes of observational studies in UC and to evaluate how the number and type of variables included and the length of follow‐up affect the frequency of patients that achieve these outcomes.Methods: A systematic literature search was carried out using MEDLINE [via PubMed], Scopus, and Web of Science online databases. Observational studies that included UC patients and reported composite or aggregate outcomes were identified. A set of variables considered to be representative of progressive or disabling UC was defined, the proportion of patients attaining the outcomes was determined and a random‐effects meta‐analysis was performed by dividing the identified studies into subgroups according to different criteria of interest.Results: A total of 10,264 records were identified in the systematic search, of which 33 were retained for qualitative analysis and 20 were included in the meta‐analysis. The mean frequency for composite outcomes was 0.363 [95% confidence interval (CI) 0.323‐0.403]. The frequency of composite outcome for the subgroup of studies that included the variable “Biologics” was significantly higher than for those in which this variable was not reported [0.410; 95% CI 0.364‐0.457 versus 0.298; 95% CI 0.232‐0.364; p = 0.006]. Composite outcomes were also more frequent as the follow‐up duration increased.Conclusion: The frequency of composite outcomes in observational studies of UC is dependent on the specific identity of the variables being reported. Moreover, longer follow‐up periods are associated with higher frequencies of composite outcomes. The evidence provided here is useful for the design of future observational studies of UC that aim to maximize the frequency of patients that achieve composite outcomes.

6 September 2017 in GE - Portuguese Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
DCDiana Carvalho
Diana Carvalho
PRPedro Russo
Pedro Russo
CBCarlos Bernardes
Carlos Bernardes
JSJoana Saiote
Joana Saiote
GRGonçalo Ramos
Gonçalo Ramos
JRJaime Ramos
Jaime Ramos
Introduction: Lymphoproliferative disorders, particularly non-Hodgkin's and Hodgkin's lymphomas, are rare in patients with inflammatory bowel diseases. The use of thiopurines and infection by Epstein-Barr virus are well-known cofactors that can raise its prevalence. Other risk factors such as disease activity and biological treatment are the subject of discussion, without enough data in the literature to confirm a potential association. Methods: We report a case of Hodgkin's lymphoma in a patient who had been treated with azathioprine and was on long-term monotherapy with infliximab. Conclusions: We stress the importance of recognizing the possible occurrence of a lymphoproliferative disorder in association with anti-tumor necrosis factor-α therapy

26 January 2017 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
CBC. Bernardes
C. Bernardes
RLR. Loureiro
R. Loureiro
DCD. Carvalho
D. Carvalho
VBV. Borges
V. Borges
PRP. Russo
P. Russo
JRJ. Ramos
J. Ramos
Background: Inflammatory bowel disease (IBD) is often diagnosed in women of childbearing age, which may influence therapeutic decisions in those patients. Despite several studies have suggested the safety of tumour necrosis alpha antagonists (anti-TNFα) during pregnancy, there are still concerns regarding their long-term effect, and the optimal timing for their discontinuation is not yet fully established. The aim of this study was to evaluate IBD and pregnancy-related outcomes in patients who were treated with anti-TNFα drugs, as well as their children's safety. Methods: We conducted a retrospective review of women with IBD who received anti-TNFα therapy during pregnancy between 2004 and 2016. Clinical characteristics, disease and drugs history, pregnancy and neonatal complications and data regarding children's growth, development and medical history were collected. Results: We analysed 22 pregnancies in 17 women: 15 with Crohn's disease (CD), 2 with ulcerative colitis (UC), mean age of 30±5 years, range 19–38 years. During gestation, 13 patients used infliximab and 9 used adalimumab; 41% of them (n=9) had concomitant treatment with azathioprine/6-mercaptopurine. Ninety-one percent of women (20/22) had inactive disease before pregnancy. Last anti-TNFα administration was performed between the 20th and the 35th week of pregnancy (median of 28 weeks gestation). The relapse rate during pregnancy and puerperal period was 14% (n=3): an UC patient and a CD patient had a flare in the 3rd and in the 1st trimester, respectively, both medically treated; a woman with CD, who had moderately active disease at conception, relapsed in the 2nd and required surgery in the 3rd trimester. Of the 22 cases, 21 were full pregnancies (one of which a twin pregnancy) and 1 is still in course. Apart from a case of twin-twin transfusion syndrome (successfully treated with good outcome) and a low-birth weight infant (in the patient who relapsed and underwent surgery), there were no other complications, including stillbirth, preterm birth or congenital anomalies. All children (n=22, from 21 full pregnancies; mean age of 62±40 months, range 1–134 months) had normal growth and the rate and severity of infections was not different from those observed in the pediatric non-IBD population. Conclusions: In our study, the vast majority of women had inactive disease at conception and biological therapy was effective in maintaining their clinical remission. Moreover, anti-TNFα treatment was not associated with an increased risk of pregnancy/neonatal events, infectious complications or childhood development disorders. Our data reinforces that controlling the disease, either before and during gestation, may be more important to pregnancy and IBD outcomes than the administered therapy.